SAB Biotherapeutics

SABSNasdaq United States Health Care Biotechnology: Biological Products (No Diagnostic Substances)

Market cap

$318.452 M

$3.50 +3.25%

Close of 22 Sept 2026

Revenue

$0.00

#3637 by revenue

Earnings

$13.3M

#1990 by earnings

Shares outstanding

90,986,368

Latest filing cover page

P/E ratio

24.0

Cap ÷ net income

Other share classes

SAB Biotherapeutics lists more than one class of stock. Company figures above cover all classes combined.

SABSW

Biotechnology: Biological Products (No Diagnostic Substances), ranked by market cap

All 160 →

#82Lexeo TherapeuticsLXEO$333.9M
#83Inhibikase TherapeuticsIKT$322.3M
#84SAB BiotherapeuticsSABS$318.5M
#85Fate TherapeuticsFATE$309.1M
#86Palisade BioPALI$294.5M

What if SAB Biotherapeutics were worth as much as…

Open the what-if tool →

Gold $30.2T

$332,291.20

Per share 94,940× higher

Bitcoin $1.74T

$19,141.93

Per share 5,469× higher

Nvidia $5.52T

$60,621.91

Per share 17,321× higher

Or at a round number

$500.0M $1.00B $2.00B $5.00B

Where these numbers come from

Share counts and financials for SAB Biotherapeutics are taken from its own SEC filings via EDGAR: public record, not an estimate. Market cap is shares outstanding multiplied by the latest close. Last updated 23 Sept 2026. Read the methodology.